Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HBAN stock price vs ABBV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABBV's multiple
Needs ABBV P/E.
Implied fair value · at HBAN's multiple
Needs HBAN P/E.
Live quote
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability edge
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: HBAN FY 2025 (ended Dec 31, 2025) · ABBV FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
$18.20B
Price / tangible book
—
Price / book
—
Return on equity
9.1%
Return on assets
1.0%
Efficiency ratio
55.7%
Price / book
Market cap
—
Tangible equity
-$91.55B
Price / tangible book
—
Price / book
—
Return on equity
-129.2%
Return on assets
3.2%
Efficiency ratio
—
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Huntington Bancshares Incorporated · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
AbbVie Inc. · implied price per share
Bear
$53.48
Base
$62.92
Bull
$72.36
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.76x
-19.88x
Net debt / EBITDA
Leverage against operating earnings
0.03x
2.90x
Cash and equivalents
Liquid reserves on the balance sheet
$18.14B
$5.26B
Total debt
Interest-bearing obligations outstanding
$18.48B
$65.00B
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JPMorgan Chase & Co.
HBAN vs JPM
Bank of America Corporation
HBAN vs BAC
Wells Fargo & Company
HBAN vs WFC
Citigroup Inc.
HBAN vs C
PNC FINANCIAL SERVICES GROUP, INC.
HBAN vs PNC
Pfizer Inc.
HBAN vs PFE
Johnson & Johnson
HBAN vs JNJ
Merck & Co., Inc.
HBAN vs MRK
Eli Lilly and Company
HBAN vs LLY
Amgen Inc.
HBAN vs AMGN
Gilead Sciences, Inc.
HBAN vs GILD
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
